ribosomal modification protein rimK like family member B pseudogene 2Genealiases: []
Q-omics provides the consensus-scored RIMKLBP2 profile across patient tissues and cancer cell-line models. RIMKLBP2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RIMKLBP2 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, RIMKLBP2 RNA expression shows 19,772 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, LIHC, and THYM as cancer lineages where RIMKLBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIMKLBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIMKLBP2 survival associations across molecular data types. RIMKLBP2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIMKLBP2 RNA expression–survival associations across cancer types. High RIMKLBP2 expression shows unfavorable associations in ACC, THCA, UVM, MESO and LGG, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RIMKLBP2 RNA expression.
This table summarizes RIMKLBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RIMKLBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIMKLBP2 shows lower tumor expression in UCEC and higher tumor expression in LIHC, HNSC, BLCA, CHOL and KIRP. The LIHC box plot shows higher RIMKLBP2 RNA expression in tumor versus normal tissue (log2 FC = +0.460, t-test p < 0.001).
This table shows molecular features associated with RIMKLBP2 in patient tissues and cancer cell lines. In patient samples, RIMKLBP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
